收藏切换
Key changes in the 2026 edition of the Good Clinical Practice regarding safety reviews and corresponding measures
收藏切换
Man GAO1, Xue-qing PENG1, Kai-hui WU1, Ji-yin ZHOU2, *
Chinese Journal of New Drugs | 2026, 35(19) : 2038 - 2047
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(19): 2038-2047
Key changes in the 2026 edition of the Good Clinical Practice regarding safety reviews and corresponding measures
Full
Man GAO1, Xue-qing PENG1, Kai-hui WU1, Ji-yin ZHOU2, *
Affiliations
  • 1 Changde Hospital, Xiangya School of Medicine, Central South University (the First People’s Hospital of Changde), Changde 415000, China
  • 2 Clinical Medical Research Center, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Published: 2026-10-15 doi: 10.20251/j.cnki.1003-3734.2026.19.003
Outline
收藏切换

AbstractThe new edition of the Good Clinical Practice (GCP) was officially issued on June 8, 2026. It fully incorporates the core principles of the ICH guideline E6(R3): Guideline for Good Clinical Practice and fundamentally reshapes the clinical trial safety review system. Through a comparative analysis of the 2026 and 2020 versions of the GCP, and with reference to supporting documents such as the Technical Guidance on the Collection, Analysis, and Reporting of Expedited Safety Reports by Sponsors During Clinical Trials (Draft for Comment) (2026), this study provides an in-depth analysis of the key changes and underlying logic of the safety review under the new regulations. The study concludes that the new regulations comprehensively introduce the concept of “risk-proportionality,” further optimizing the safety reporting mechanism, the content of safety reviews, and the approaches of safety review, while clarifying the responsibilities of relevant parties. To adapt to these changes, safety reviews under the new regulations should establish an ethics review system aligned with the new requirements by strengthening the review capabilities of ethics committee members, optimizing review procedures, refining the content and requirements of safety reviews, and enhancing multi-stakeholder collaboration.

Good Clinical Practice  /  safety review  /  ethics review committee  /  risk management
高漫, 彭学清, 吴开慧, 周吉银. 《药物临床试验质量管理规范》2026年版对安全性审查的重点变化及应对举措. 中国新药杂志, 2026 , 35 (19) : 2038 -2047 . DOI: 10.20251/j.cnki.1003-3734.2026.19.003
Man GAO, Xue-qing PENG, Kai-hui WU, Ji-yin ZHOU. Key changes in the 2026 edition of the Good Clinical Practice regarding safety reviews and corresponding measures[J]. Chinese Journal of New Drugs, 2026 , 35 (19) : 2038 -2047 . DOI: 10.20251/j.cnki.1003-3734.2026.19.003
Year 2026 volume 35 Issue 19
64
9
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.19.003
  • Receive Date:2026-06-20
  • Online Date:2026-10-29
  • Published:2026-10-15
Article Data
Affiliations
History
  • Received:2026-06-20
Funding
Affiliations
    1 Changde Hospital, Xiangya School of Medicine, Central South University (the First People’s Hospital of Changde), Changde 415000, China
    2 Clinical Medical Research Center, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.19.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT